Abstract: A driving route matching method, apparatus, and storage medium. The method includes: obtaining a route to be retrieved, the route including a retrieval start point and a retrieval end point; performing a search in a database of existing routes, and selecting the existing routes passing through grids within a predetermined range around the start point as routes available for the start point; performing a search in the database of the existing routes, and selecting the existing routes passing through grids within a predetermined range around the search endpoint as routes available for the end point; calculating intersections of the routes available for the start point and the routes available for the end point, and using the routes in the intersections as candidate routes; and screening the candidate routes according to detouring distances. The driving route matching method and apparatus enable a remarkable improvement in the efficiency of driving route matching.

Abstract: Embodiments of the present disclosure relate to adaptive RFID communication. A tag device includes a storage configured to store content that is executable by a proxy device associated with a reader device. The tag device includes a communication component configured to transmit the content to the reader device, the content, when executed by the proxy device, causing an action associated with the tag device to be performed.

Abstract: A communication device, user equipment, and a communication system are provided. The communication device comprises a Context ID check module to check a Context ID (CID) of a current default bearer in response to a disconnect command from a host; wherein, if the Context ID check module determines that there is only a first default bearer activated, the Context ID check module releases the connection between the communication device and the host without deactivating the first default bearer; and if the Context ID check module determines that there are two default bearers activated, the Context ID check module releases the second default bearer.

Abstract: A method and apparatus for managing registration of a plurality of wireless communication devices to a plurality of different networks with a controller. The controller controls registration and registration priority to each of the plurality of wireless communication devices. Based on the registration priority, the registration limits of each network, and an amount of wireless communication device registrations associated with a wireless communication device user, the controller controls registration of each of the wireless communication devices across the plurality of networks. Controlling registration includes denying registration to a wireless communication device user that has a preexisting network connection, deregistering a wireless communication device that has more than one network connection, and registering/deregistering wireless communication devices based on the registration priority of each wireless communication device.

Abstract: A mobile radio has selectable transmit and receive channels, and is in a talkgroup that has a primary channel and multiple auxiliary channels. The mobile radio receives a broadcast-start command, and responsively selects its transmit channel to be the primary channel (if available) or an inactive auxiliary channel (if the primary channel is not available). The mobile radio receives user media via its user interface, and transmits that received user media on its selected transmit channel. The mobile radio scans for an auxiliary channel transitioning from inactive to active. Responsive to detecting such a transition, the mobile radio selects that auxiliary channel as its receive channel. The mobile radio mixes inbound media received on its selected receive channel with user media received via its user interface, and transmits the mixed media on its selected transmit channel.

Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: A mobile radio has selectable transmit and receive channels, and is in a talkgroup that has a primary channel and multiple auxiliary channels. The mobile radio receives a broadcast-start command, and responsively selects its transmit channel to be the primary channel (if available) or an inactive auxiliary channel (if the primary channel is not available). The mobile radio receives user media via its user interface, and transmits that received user media on its selected transmit channel. The mobile radio scans for an auxiliary channel transitioning from inactive to active. Responsive to detecting such a transition, the mobile radio selects that auxiliary channel as its receive channel. The mobile radio mixes inbound media received on its selected receive channel with user media received via its user interface, and transmits the mixed media on its selected transmit channel.

Abstract: An encryption method includes: converting a section of express information into a binary sequence, grouping the binary sequence into a plurality of group data, and aligning each group data into an information matrix; converting the information matrix into a corresponding a basic group information matrix; randomly choosing a reference DNA sequence from a gene library, and aligning the reference DNA sequence into a basic group transition matrix, using the basic group transition matrix to convert the basic group information matrix into an encrypted information matrix, and exploding the encrypted information matrix to obtain a basic group information sequence; generating a primer for the basic group information sequence, and adding the primer before and behind the primer generator to obtain a completed DNA sequence; and synthesizing a DNA matter based on the completed DNA sequence.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor which may be used medicaments.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (V): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention discloses a light system with energy management function and control method thereof. The lighting system based on plastic forming technology. That is an application of energy storage module that balances the off-peak electricity to be used at noon. The principal merit is replacing the independent emergency lighting equipment attached at wall. By comparing these two systems, it is realized that the illumination and cost are much better than the traditional type of emergency lighting equipment due to the weathering quality of using plastic forming technology. Furthermore, this invention is much available be applied in outdoor.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y1 receptor and may be used as medicaments in the treatment and/or prophylaxis of thromboembolic disorders.

Abstract: The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Abstract: The present invention provides compounds of Formula (VIII): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.